Calculate the Eczema Area and Severity Index (EASI) for atopic dermatitis. Assesses erythema, edema, excoriation, and lichenification across 4 body regions.
The Eczema Area and Severity Index (EASI) is the primary validated outcome measure for assessing atopic dermatitis (eczema) severity. It evaluates four clinical signs — erythema, edema/papulation, excoriation, and lichenification — across four body regions (head/neck, trunk, upper limbs, lower limbs), weighted by body surface area proportion.
EASI scores range from 0 to 72, with severity classified as clear (0), mild (0.1-7), moderate (7.1-21), severe (21.1-50), and very severe (50.1-72). The EASI-50 endpoint — a 50% reduction from baseline — is the most commonly used primary outcome in clinical trials for new eczema therapies.
This calculator facilitates systematic EASI scoring for clinical practice, treatment monitoring, and research documentation. It provides region-specific breakdowns to identify which body areas are most affected and track improvement over time. Check the example with realistic values before reporting. Use the steps shown to verify rounding and units. Cross-check this output using a known reference case. Use the example pattern when troubleshooting unexpected results.
Atopic dermatitis affects up to 20% of children and 10% of adults worldwide. Objective severity assessment is essential for treatment decisions, therapy monitoring, and clinical trial endpoints. The EASI provides standardized, reproducible severity scoring that enables comparison across visits and between patients.
With the advent of biologic therapies (dupilumab, tralokinumab), objective EASI documentation is often required for insurance authorization and treatment eligibility.
EASI = 0.1 × (Head signs sum × area) + 0.3 × (Trunk signs sum × area) + 0.2 × (UL signs sum × area) + 0.4 × (LL signs sum × area) Signs sum = Erythema (0-3) + Edema (0-3) + Excoriation (0-3) + Lichenification (0-3) Area: 0-6 scale (0%, 1-9%, 10-29%, 30-49%, 50-69%, 70-89%, 90-100%) Range: 0-72
Result: EASI 12.0 — Moderate
With moderate area involvement (2-3) and mild-moderate sign intensity across all regions, the weighted EASI calculates to 12.0, falling in the moderate severity range. Treatment with mid-potency topicals and calcineurin inhibitors is appropriate.
EASI has become the gold standard primary endpoint for atopic dermatitis clinical trials following the Harmonizing Outcome Measures for Eczema (HOME) initiative recommendations. Major trials for dupilumab (SOLO 1&2, LIBERTY AD), baricitinib (BREEZE-AD), upadacitinib (Measure Up), and abrocitinib (JADE) all used EASI-75 as primary or key secondary endpoints.
Mild EASI (0-7): Emollients + intermittent low-potency topical corticosteroids. Moderate EASI (7-21): Regular mid-potency topicals + topical calcineurin inhibitors + consider phototherapy. Severe EASI (21-50): High-potency topicals + systemic therapy (cyclosporine, methotrexate, or biologics). Very severe (>50): Urgent biologic or systemic therapy + dermatology referral.
Lichenification is often the most difficult sign to grade and improves most slowly with treatment. Excoriation reflects patient scratching behavior which may improve rapidly with itch control (antihistamines, behavioral strategies). Edema/papulation is the most sensitive sign to acute flares and typically responds first to treatment.
EASI-50 indicates a 50% reduction from baseline EASI score. It is the most widely accepted definition of clinically meaningful improvement in eczema clinical trials and is used by regulatory agencies (FDA/EMA) for drug approval endpoints. EASI-75 (75% improvement) is an increasingly used stringent endpoint.
In clinical practice, every 2-4 weeks during active treatment optimization, then every 3-6 months during maintenance. In clinical trials, every 2-4 weeks. Consistent timing relative to treatment application is important for valid comparisons.
Inter-observer reliability for EASI is good (ICC 0.8-0.9) among trained assessors, superior to most other eczema scores. Training and practice improve consistency. Video-based training resources are available through dermatology organizations.
EASI evaluates only signs and area (physician-assessed), while SCORAD also includes patient-reported symptoms (pruritus, sleep loss). EASI is preferred for clinical trials due to better reliability. SCORAD provides a more holistic view including patient burden.
Most guidelines recommend biologic therapy (dupilumab) for moderate-to-severe AD (EASI ≥16 or ≥21, varies by guideline) that has failed conventional systemic therapy. Insurance criteria often require documented EASI scores and treatment failure history.
Yes. EASI is validated for children aged ≥2 years. For infants, modified scoring accounts for proportionally larger head area. The same severity cutoffs apply, though treatment thresholds differ in pediatric populations.